Genotyping Assay Market is Segmented By Product (Reagents & Kits, Instruments, Other),By Technology (PCR, Microarrays, Sequencing, Capillary Electrophoresis, Other), By End-User (Pharmaceutical and Biopharmaceutical Companies, Diagnostic and Research Laboratories, Other), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Genotyping assay market size was valued growing at a CAGR of 19.99 % during the forecast period (2024-2031). Genotyping is the process of determining differences in an individual's genetic make-up (genotype) by examining the individual's DNA sequence and comparing it to the sequence of another individual or a reference sequence using biological assays.
Genotyping Assay Market Dynamics
The factors influencing the Genotyping assay market are the growing importance of genotyping assay, and the technological advancements are expected to drive the market growth.
The growing importance of genotyping assay is expected to drive the market growth in the forecast period
Researchers can use genotyping to investigate genetic variants such as single nucleotide polymorphisms (SNPs) and large structural changes in DNA. High-throughput genomic technologies like next-generation sequencing (NGS) and microarrays allow for a more in-depth understanding of disease aetiology at the molecular level.
With multiple genomic targets potentially contributing to disease, an analysis must be flexible and precise. Data analysis tools for SNP genotyping and copy number variation (CNV) can analyze results for millions of markers and probes and detect sample outliers, providing insight into the functional consequences of genetic variation. Genotyping can help us understand disease mechanisms, predict an individual's risk of developing certain diseases, and even aid in developing personalized therapies. Biosystems for Applied Research TaqMan SNP genotyping assays have been used to identify variants linked to blood disorders and a variety of other diseases. TaqMan SNP genotyping assays require a double-stranded DNA template, the Taq polymerase enzyme, and two forward and reverse primers specific to the amplified sequence. Unlike gene expression qPCR, SNP detection necessitates using two probes with different fluorescent reporters. This allows homozygous and heterozygous samples to be distinguished.
Limitations associated with genotyping assay is expected to hamper the market growth
WGR genotyping has traditionally been carried out using paired-end Illumina technology, which, according to a survey, costs approximately $400 per sample for a genome of 1 Gb and 10 average sequencing depth. WGR-based GWAS, which typically involves a few hundred individuals, may cost several hundred dollars for crops with large genomes. Reduced average sequencing depth can reduce WGR costs; however, this may result in an unacceptable number of genotyping errors.
Furthermore, although genotyping errors affect most data and can significantly impact a study's biological conclusions, they are too often overlooked. Genotyping errors can arise from various complex and sometimes cryptic causes, including the primary DNA sequence, low quality or quantity of the DNA sample, biochemical artifacts, or human factors.
COVID-19 Impact Analysis
Several alarming VOC lineages have been linked to increased transmissibility, virulence, or the ability to evade the immune response gained from prior infection or vaccination. Mutations in the viral genome of these variants are associated with a change in 'fitness' or are unique to their lineage and can be used as genotyping genetic markers. It distinguishes between the wild-type (WT) strain and other variants. To combat these new variants, including the Omicron/B.1.1.529 variant, constant monitoring and the rapid development of novel early-detection tools are required. Although next-generation sequencing (NGS) methods exist for variant surveillance, qRT-PCR and Pyrosequencing provide significantly faster options for highly sensitive detection of specific mutations and VOCs, with same-day genotyping results. QIAGEN applies its expertise in assay design for these two technologies to provide the lab with high-performance genotyping assays. Hence, the global genotyping assay market is expected to be positively impacted.
Genotyping Assay Market Segment Analysis
By technology, the PCR segment is expected to dominate the market in the forecast period
PCR genotyping employs the widely used polymerase chain reaction technique for genetic analysis. DNA or RNA sequences are amplified with specific primers and electrophoretically analyzed for size and quality before being extracted and purified. Genotyping enables researchers to investigate large structural variations and small genetic changes in DNA, such as single nucleotide polymorphisms (SNPs). Real-time PCR is a high throughput genotyping method that uses molecular probes to produce quick and accurate results. Real-time PCR is a high throughput genotyping method that uses molecular probes to produce quick and accurate results. Our qPCRBIO Probe Mixes are compatible with all dual-labeled allele-specific probes and can be used for reliable allelic discrimination. Another real-time genotyping system is High-Resolution Melt, a post-PCR application (HRM).
Many companies are launching PCR genotyping assay products and are expected to drive market growth. For instance, on 2nd February 2021, Novacyt S.A launched PCR genotyping assay portfolio under the brand name SNPsig, to diagnose new variants of SARS-CoV-2.
Genotyping Assay Market Scope
Metrics | Details |
Market CAGR | 19.99% |
Segments Covered | By Product, By Technology, By End-User, and By Region |
Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
Fastest Growing Region | Asia Pacific |
Largest Market Share | North America |
Genotyping Assay Market Geographical Analysis
North America region is expected to hold the largest market share in the global genotyping assay market
The greater technological and government support and the presence of major players in the region are expected to drive the market growth. Furthermore, increased R&D funding is expected to fuel market growth over the forecast period. Thermo Fisher Scientific is based in the United States that manufactures and distributes scientific instruments, reagents and consumables, and software services. TaqMan SNP Genotyping Assay uses TaqMan 5'nuclease chemistry to amplify and detect specific polymorphisms in purified genomic DNA samples. Each assay uses two sequence-specific primers, and two TaqMan minor groove binder (MGB) probes with non-fluorescent quenchers to genotype individuals for a single nucleotide polymorphism (SNP) (NFQ).
Genotyping Assay Market Competitive Landscape
The global genotyping assay market is moderately competitive with mergers, acquisitions, and product launches. Some of the key players in the market are Thermo Fisher Scientific, Illumina, QIAGEN, Agilent Technologies, LGC, Biosearch Technologies, Roche Diagnostics, Fluidigm Corporation, PerkinElmer, Bio-Rad Laboratories, Integrated DNA Technologies.
Illumina
Overview: Illumina, Inc. is a company based in the United States. Illumina was founded on April 1, 1998. The company develops, manufactures, and sells integrated systems for analyzing genetic variation and biological function.
Product Portfolio: The iSeq 100 System is well-suited for small whole-genome sequencing (for example, bacteria, viruses, and plasmids), targeted sequencing of a subset of genes or gene regions, gene expression analysis, and 16S metagenomics.
Key Development: On January 8th, 2018, The iSeqTM 100 Sequencing System was launched by Illumina, Inc. The new next-generation sequencing (NGS) system provides exceptional data accuracy at a low capital cost, allowing Illumina technology accessible to virtually any lab.
Frequently Asked Questions
What is the Projected CAGR value of the Genotyping Assay Market?
Genotyping Assay Market is expected to grow at a CAGR of 19.99% during the forecasting period 2024-2031.
Which region controlled the global market during 2024-2031?
North America region Controls the Genotyping Assay Market during 2024-2031
Which is the fastest growing region in the Genotyping Assay Market?
Among all regions, Asia Pacific is the fastest growing market share during the forecast period
